We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03818581
Recruitment Status : Active, not recruiting
First Posted : January 28, 2019
Last Update Posted : September 2, 2021
Information provided by (Responsible Party):
John Winkelman, MD, PhD, Massachusetts General Hospital

Brief Summary:
The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Insomnia Sleep Disorder Inflammation Drug: Suvorexant Other: Placebo Phase 4

Detailed Description:
Type 2 diabetes results from a progressive insulin secretory defect on the background of insulin resistance and is a growing pandemic and a leading cause of morbidity and mortality. Sleep disturbance is one of the underappreciated and important features of Type 2 diabetes, and may contribute to the development of the disease. In those with established Type 2 diabetes, there is emerging evidence from cross-sectional studies that sleep disturbance affects glycemic control. Although cross-sectional studies suggest a relationship between sleep disturbance and glycemic control in Type 2 diabetes, causality is best investigated by interventional studies. Suvorexant has a comparatively benign side effect profile compared to many of the hypnotic agents typically prescribed for insomnia. The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST), as well as subjective wake after sleep onset, Insomnia Severity Index, HbA1c levels and insulin sensitivity, inflammatory markers, and other subjective sleep endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 107 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Sequential Parallel Comparison Design: subjects will be randomized in a 1:2 ratio to suvorexant 10-20 mg or equivalent placebo for six weeks, followed by re-randomization of placebo non-responders to either suvorexant or placebo in a 1:1 design for six weeks.
Masking: Double (Participant, Investigator)
Masking Description: The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study. An unmasked research coordinator will be responsible for assessing mid-point outcomes on the sleep diaries and communicating with the pharmacy for re-randomization medication orders.
Primary Purpose: Treatment
Official Title: Effect of Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes: A Randomized 3-month Clinical Trial Using a Sequential Parallel Comparison Design
Actual Study Start Date : March 15, 2019
Estimated Primary Completion Date : September 15, 2021
Estimated Study Completion Date : September 15, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Suvorexant

Arm Intervention/treatment
Active Comparator: Treatment Group Drug: Suvorexant
10-mg or 20-mg Suvorexant capsules
Other Name: Belsomra

Placebo Comparator: Placebo Responders Other: Placebo
Matching placebo capsules

Active Comparator: Placebo Non-responders Re-randomized to Treatment Drug: Suvorexant
10-mg or 20-mg Suvorexant capsules
Other Name: Belsomra

Other: Placebo
Matching placebo capsules

Placebo Comparator: Placebo Non-responders Re-randomized to Placebo Other: Placebo
Matching placebo capsules

Primary Outcome Measures :
  1. Subjective Total Sleep Time [ Time Frame: 2 weeks ]
    Total sleep time as reported on daily sleep diaries

Secondary Outcome Measures :
  1. Subjective Wake After Sleep Onset [ Time Frame: 2 weeks ]
    Total time awake after sleep onset as reported on daily sleep diaries

  2. Insomnia Severity Index [ Time Frame: 2 weeks ]
    A validated tool to measure insomnia severity, on a scale of 0-28, with a higher score representing greater insomnia severity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women of any ethnic origin
  2. Written informed consent is obtained
  3. Speaks and writes in English
  4. A willingness and ability to comply with study procedures.
  5. Age 25-75 years
  6. Diagnosis of Type 2 diabetes with suboptimally controlled blood sugar determined by HbA1c > 6.5% (and < 10.0%) at both the screening and randomization visits
  7. No changes in diabetes medication in the previous month
  8. DSM-5 criteria for Insomnia Disorder
  9. Score on the Insomnia Severity Index (ISI) measure >10, indicating at least a moderate level of insomnia symptoms2
  10. Report a total sleep time ≤ 6.5 hours and combined sleep onset latency (SOL) and wake after sleep onset (WASO) > 45 minutes on 7 or more of the 14 nightly sleep logs during both the initial 2-week screening period and the two-week screening run-in period. Combined SOL and WASO does not decrease by more than 50% on the 2-week sleep diary obtained between the screening visit and the randomization visit.

Exclusion Criteria:

  1. Sleep and medical factors:

    1. Diagnosis of severe obstructive sleep apnea not using CPAP (can be included if CPAP adherent), or other untreated primary sleep disorders (e.g. narcolepsy, moderate to severe restless legs syndrome)
    2. Shift workers
    3. Use of hypnotic medications more than twice per week in the past month
    4. Unwillingness to not use sedative-hypnotics (other than suvorexant) during the study period
    5. Unwillingness to maintain stable diabetes medication during the study unless medically indicated
    6. Positive urine toxic screen for any drugs of abuse other than marijuana at Screening Visit
    7. HbA1c ≥ 10.0% at either the screening or randomization visit
  2. Psychiatric factors:

    1. Current major depressive episode, by report and as indicated by the Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR).
    2. Subjects with active or unstable major psychiatric disorder, who, in the investigator's judgement, require further treatment.
    3. Current alcohol/substance use disorder
  3. Medical factors:

    1. Renal or hepatic disease judged to interfere with drug metabolism and excretion
    2. Pregnant or breastfeeding
    3. Malignancy within past 2 years
    4. Surgery within past 3 months
    5. Neurological disorder or cardiovascular disease raising safety concerns about use of suvorexant and/or judged to interfere with ability to assess efficacy of the treatment
    6. Medical instability considered to interfere with study procedures
    7. Concomitant medications with drug interaction or co-administration concerns
    8. Contraindications or allergic responses to suvorexant
    9. History of being treated with suvorexant
  4. Lifestyle and other factors:

    1. Travel across two time-zones during the week prior to enrollment
    2. Greater than 6 cups of coffee per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03818581

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: John W Winkelman, MD/PhD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: John Winkelman, MD, PhD, Chief, Sleep Disorders Clinical Research Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT03818581    
Other Study ID Numbers: 2019P000076
First Posted: January 28, 2019    Key Record Dates
Last Update Posted: September 2, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Wake Disorders
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Sleep Disorders, Intrinsic
Nervous System Diseases
Mental Disorders
Neurologic Manifestations
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Orexin Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action